In particular, the MMP-2 cleaved gal-3 protein is known to be correlated with angiogenesis in tumor progression in the early stage [64], leading Nangia-Makker et al. to suggest that gal-3C can be a new therapeutic target [41]. This evidence concerns the gene LGALS3 and neoplasm.